Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals

Heidi I L Jacobs, Trey Hedden, Aaron P Schultz, Jorge Sepulcre, Rodrigo D Perea, Rebecca E Amariglio, Kathryn V Papp, Dorene M Rentz, Reisa A Sperling, Keith A Johnson, Heidi I L Jacobs, Trey Hedden, Aaron P Schultz, Jorge Sepulcre, Rodrigo D Perea, Rebecca E Amariglio, Kathryn V Papp, Dorene M Rentz, Reisa A Sperling, Keith A Johnson

Abstract

Animal models of Alzheimer's disease have suggested that tau pathology propagation, facilitated by amyloid pathology, may occur along connected pathways. To investigate these ideas in humans, we combined amyloid scans with longitudinal data on white matter connectivity, hippocampal volume, tau positron emission tomography and memory performance in 256 cognitively healthy older individuals. Lower baseline hippocampal volume was associated with increased mean diffusivity of the connecting hippocampal cingulum bundle (HCB). HCB diffusivity predicted tau accumulation in the downstream-connected posterior cingulate cortex in amyloid-positive but not in amyloid-negative individuals. Furthermore, HCB diffusivity predicted memory decline in amyloid-positive individuals with high posterior cingulate cortex tau binding. Our results provide in vivo evidence that higher amyloid pathology strengthens the association between HCB diffusivity and tau accumulation in the downstream posterior cingulate cortex and facilitates memory decline. This confirms amyloid's crucial role in potentiating neural vulnerability and memory decline marking the onset of preclinical Alzheimer's disease.

Figures

Figure 1. The hypothesized model motivating our…
Figure 1. The hypothesized model motivating our design and analyses
The relationships that were specifically analyzed in the current manuscript are within the blue box. The green boxes hypothesize that hippocampal volume loss is resulting from neuronal damage, partially due to early tau pathology in the medial temporal lobe. As tau PET was acquired later in the study and thus this information was not available at baseline, we could not examine the green boxes. The relationship between hippocampal volume and diffusivity of the hippocampal cingulum bundle was analyzed using both baseline measures of hippocampal volume and change in hippocampal volume over time. Abbreviations: MTL = medial temporal lobe, PCC = posterior cingulate cortex.
Figure 2. Associations between hippocampal volume and…
Figure 2. Associations between hippocampal volume and change in mean diffusivity in the HCB and UF
The orange boxes depict part of the model that is being investigated: we hypothesized that hippocampal volume predicts annual change in white matter diffusivity of the HCB (n= 256 unique participants) and not of the UF (n=253 unique participants). Figures below the models show the anatomical localization of the hippocampus (green), the HCB (red) and the UF (yellow) and the investigated link (arrow). The line plots (top row = left, bottom row = right hemisphere) show that right hippocampal volume predicted increased MD of the right HCB over time (left, bottom corner). No significant associations were found between hippocampal volume and changes in MD of the UF. In all line plots, estimated marginal means of the moderation by hippocampal volume are plotted at the mean and ± 1 standard deviation, but analyses were done continuously using linear mixed effects models. Shaded areas around the fit lines show the 95% confidence interval. All p-values are two-sided and unadjusted for multiple comparisons.
Figure 3. Associations between tract diffusivity and…
Figure 3. Associations between tract diffusivity and tau accumulation in the PCC or inferior temporal
The orange/pink boxes depict part of the model that is being investigated as depicted in Figure 1 (tract diffusivity predicting annual change in tau binding). The first column depicts first the anatomical localization of the HCB (red), the PCC (blue) and the investigated link (arrow). The line plots (top = left, bottom = right hemisphere) show that higher levels of MD in the right HCB predicted increased PCC tau accumulation (bottom left, in the black box, n=141 unique participants). The middle column shows the associations between the control tract, UF (yellow) and the PCC (blue). No significant associations were found for left or right, consistent with our hypothesis (n=139 unique participants). The right column shows the associations between the HCB (red) and the control tau region (IT cortex). No significant associations were found for left or right (n=141 unique participants). The zoomed in section at the bottom shows the link between amyloid pathology, tract diffusivity and annual change in PCC tau accumulation (model depicted in the boxes). The line plots show that the association between right HCB diffusivity and right PCC tau change is only found in amyloid positive individuals (right, n=36 unique participants) and not amyloid negative individuals (left, n=103 unique participants). In all line plots, time was defined at the time since the baseline MRI measurement and MD of the tracts is depicted in mean ± 1 standard deviation, but analyses were done continuously using linear mixed effects models. Shaded areas around the fit lines show the 95% confidence interval. All p-values are two-sided and unadjusted for multiple comparisons. Abbreviations: HCB = Hippocampal cingulum bundle, UF = uncinate fasciculus, PCC = Posterior cingulate cortex
Figure 4. Associations between tract diffusivity, tau…
Figure 4. Associations between tract diffusivity, tau accumulation in the PCC, amyloid pathology and memory performance
The colored boxes depict part of the investigated model in Figure 1. The line plots show the breakdown of the estimates from linear mixed models examining changes memory performance predicted by hippocampal cingulum tract diffusivity in low tau (left a, n=93 unique participants) and high tau (right a,n=48 unique participants) individuals. Panel b investigated the associations between right hippocampal cingulum diffusivity and memory performance in individuals with high PCC tau who either were amyloid negative (n=30 unique participants) or positive (n=18 unique participants). The plots show a significant change in memory in individuals with high PCC tau and high amyloid levels (n=18, right b). In all line plots, HCB MD is depicted in mean ± 1 standard deviation, but analyses were done continuously using linear mixed effects models. Shaded areas around the fit lines show the 95% confidence interval. All p-values are two-sided and unadjusted for multiple comparisons. Abbreviations: HCB = Hippocampal cingulum bundle, PCC = Posterior cingulate cortex, SUVr = Standardized uptake value ratio.

References

    1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259.
    1. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92:197–201.
    1. Ahmed Z, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127:667–683.
    1. Khan UA, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat. Neurosci. 2014;17:304–311.
    1. Hu W, et al. Hyperphosphorylation determines both the spread and the morphology of tau pathology. Alzheimers Dement. 2016;12:1066–1077.
    1. Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131:27–48.
    1. Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011;121:589–595.
    1. Wu JW, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 2016;19:1085–1092.
    1. de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685–697.
    1. Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 2016;17:251–260.
    1. Pooler AM, et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta Neuropathol. Commun. 2015;3:14.
    1. Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2016;79:110–119.
    1. Marquie M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 2015;78:787–800.
    1. Scholl M, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89:971–982.
    1. Madden DJ, Bennett IJ, Song AW. Cerebral white matter integrity and cognitive aging: contributions from diffusion tensor imaging. Neuropsychol. Rev. 2009;19:415–435.
    1. Jones DK, Leemans A. Diffusion tensor imaging. Methods Mol. Biol. 2011;711:127–144.
    1. Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004;55:306–319.
    1. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015;138:2814–2833.
    1. Villain N, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain. 2010;133:3301–3314.
    1. Jicha GA, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 2006;63:674–681.
    1. Heilbronner SR, Haber SN. Frontal cortical and subcortical projections provide a basis for segmenting the cingulum bundle: implications for neuroimaging and psychiatric disorders. J. Neurosci. 2014;34:10041–10054.
    1. Sepulcre J, et al. In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. J. Neurosci. 2016;36:7364–7374.
    1. Von Der Heide RJ, Skipper LM, Klobusicky E, Olson IR. Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis. Brain. 2013;136:1692–1707.
    1. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999;45:358–368.
    1. Delacourte A, et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp. Gerontol. 2002;37:1291–1296.
    1. Dagley A, et al. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017;144:255–258.
    1. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9:195–207.
    1. Logan J, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990;10:740–747.
    1. Mormino EC, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379–1385.
    1. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18:351–357.
    1. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011;68:1062–1064.
    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.
    1. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491–1495.
    1. Lewis J, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487–1491.
    1. Wheeler-Kingshott CA, Cercignani M. About "axial" and "radial" diffusivities. Magn. Reson. Med. 2009;61:1255–1260.
    1. Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009;11:909–913.
    1. Takeda S, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat. Commun. 2015;6:8490.
    1. Harris JA, et al. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428–441.
    1. Buckner RL, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J. Neurosci. 2009;29:1860–1873.
    1. Dillen KN, et al. Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. Neurobiol. Aging. 2016;44:114–126.
    1. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do? Nat. Rev. Neurosci. 2009;10:792–802.
    1. Rieckmann A, et al. Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiol. Aging. 2016;42:177–188.
    1. Stancu IC, Vasconcelos B, Terwel D, Dewachter I. Models of beta-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol. Neurodegener. 2014;9:51.
    1. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat. Rev. 2016;12:15–27.
    1. Hurtado DE, et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J. Pathol. 2010;177:1977–1988.
    1. Kuchibhotla KV, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. U.S.A. 2014;111:510–514.
    1. Gordon BA, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139:2249–2260.
    1. Frings L, et al. Asymmetries of amyloid-beta burden and neuronal dysfunction are positively correlated in Alzheimer's disease. Brain. 2015;138:3089–3099.
    1. Stefanits H, Budka H, Kovacs GG. Asymmetry of neurodegenerative disease-related pathologies: a cautionary note. Acta Neuropathol. 2012;123:449–452.
    1. Hanseeuw BJ, et al. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann. Neurol. 2017;81:583–596.
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414.
    1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975;12:189–198.
    1. Sheikh J, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. in. In: Brink TL, editor. Clinical Gerontology: A Guide to Assessment and Intervention. Haworth Press; New York: 1986. pp. 165–173.
    1. Leemans A, Jeurissen B, Sijbers J, Jones DK. 17th Annual Meeting of Intl. Soc. Mag. Reson. Med. Hawaii, USA: 2009. Explore DTI: a graphical toolbox for processing, analyzing, and visualizing diffusion MR data. in; p. 3537.
    1. Mori S, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage. 2008;40:570–582.
    1. Klein A, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009;46:786–802.
    1. Vos SB, Jones DK, Viergever MA, Leemans A. Partial volume effect as a hidden covariate in DTI analyses. Neuroimage. 2011;55:1566–1576.
    1. Nakagawa S, Schielzeth H. Repeatability for Gaussian and non-Gaussian data: a practical guide for biologists. Biol. Rev. Camb. Philos. Soc. 2010;85:935–956.
    1. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179–194.
    1. Hedden T, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 2009;29:12686–12694.
    1. Amariglio RE, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50:2880–2886.
    1. Shoup TM, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J. Labelled Comp. Radiopharm. 2013;56:736–740.
    1. Greve DN, et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage. 2014;92:225–236.
    1. Masur DM, et al. Distinguishing normal and demented elderly with the selective reminding test. J. Clin. Exp. Neuropsychol. 1989;11:615–630.
    1. Wechsler DS. Wechsler Memory Scale-Revised. Psychological-Corp; San Antonio, TX: 1987.
    1. Wechsler DS. WAIS-III, Wechsler Adult Intelligence Scale—Third Edition, Administration and Scoring Manual. The Psychological Corporation; New York: 1997.
    1. Reitan RM. Manual for administration of neuropsychological test batteries for adults and children. Reitan Neuropsychology Laboratories; Tucson, AZ: 1979.
    1. Benton AL. Contributions to Neuropsychological Assessment: A Clinical Manual. Oxford University Press; New York: 1983.
    1. Domen P, et al. Differential Time Course of Microstructural White Matter in Patients With Psychotic Disorder and Individuals at Risk: A 3-Year Follow-up Study. Schizophr. Bull. 2017;43:160–170.
    1. Mormino EC, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760–1767.
    1. Wang L, et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between beta-Amyloid and Tauopathy. JAMA Neurol. 2016;73:1070–1077.

Source: PubMed

3
Iratkozz fel